SCHEMBL18796809

SCHEMBL18796809

c1c[nH]c(Nc2cc[nH]n2)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1272593 0.78
SCHEMBL3194321 0.75 DAO (0.35)
SCHEMBL28457161 0.73
SCHEMBL834683 0.71 MAPT (0.50)
SCHEMBL2012149 0.71 MEN1 (0.53)
SCHEMBL589542 0.69 ACHE (0.36)
SCHEMBL28484112 0.69 SMN1; SMN2 (0.37)
SCHEMBL10972199 0.69 GOT1 (0.47)
SCHEMBL4667411 0.69 SCN9A (0.46)
SCHEMBL6597195 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11992531-B2 C3-carbon linked glutarimide degronimers for target protein degradation C4 THERAPEUTICS, INC. (US) 2024-05-28 US disclosed
WO-2023239750-A1 BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS C4 THERAPEUTICS, INC. (US) 2023-12-14 WO disclosed
US-20230372496-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 THERAPEUTICS, INC. (US) 2023-11-23 US disclosed
US-20230357180-A1 DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-11-09 US disclosed
CN-116723839-A Tricyclic heterobifunctional compounds for degrading target proteins C4医药公司 2023-09-08 CN disclosed
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 US disclosed
EP-4228625-A1 TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS C4 Therapeutics, Inc. (US) 2023-08-23 EP disclosed
US-20230095223-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-03-30 US disclosed
US-20230014124-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2023-01-19 US disclosed
US-11524949-B2 Degraders and Degrons for targeted protein degradation C4 THERAPEUTICS, INC. (US) 2022-12-13 US disclosed
US-20190076541-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
WO-2018237026-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2018-12-27 WO disclosed
US-20180266014-A1 FUSION PROTEIN CRYSTAL COMPRISING A MOIETY AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-09-20 US disclosed
EP-3368552-A1 A FUSION PROTEIN CRYSTAL COMPRISING A MOIETY Agency For Science, Technology And Research (SG) 2018-09-05 EP disclosed
CN-108350049-A Including partial fused protein crystal 新加坡科技研究局 2018-07-31 CN disclosed
WO-2017197051-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed
WO-2017197036-A1 SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed
WO-2017197055-A1 HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed
WO-2017197046-A1 C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2017-11-16 WO disclosed
WO-2017074268-A1 A FUSION PROTEIN CRYSTAL COMPRISING A MOIETY AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-05-04 WO disclosed